Today's word count is 842, or a 3-minute read.
Illustration: Sarah Grillo/Axios
The Supreme Court's next big Affordable Care Act case could be a huge political problem for President Trump, Axios' Sam Baker reports.
Why it matters: The Trump administration will spend the next several months urging the court to strip away some 20 million people's health insurance and to throw out protections for pre-existing conditions.
Driving the news: The court said yesterday that it will hear the challenge filed by Republican attorneys general, and supported by the Trump administration, that aims to strike down the entire ACA.
What’s next: Oral arguments in the case haven't been scheduled yet, but following the court's standard timeline, there's a decent chance those arguments could fall in October — just weeks, or potentially even days — before Election Day.
Reality check: This will be the third time the Supreme Court has held the ACA's life in its hands.
The latest edition of Health Affairs is all about the Affordable Care Act, as its 10th anniversary approaches, and serves as a well-timed reminder of why the ACA — and the lawsuit against it — matter.
Axios' Marisa Fernandez rounded up some of the Health Affairs studies' key findings. In addition to covering about 20 million people, the ACA has...
Yes, but: Substantial racial and ethnic disparities remain, especially among elderly black and Hispanic adults.
Sandoz, the generic drug unit of pharmaceutical giant Novartis, has admitted that it colluded with other companies to inflate the prices of various generic drugs and will pay $195 million to resolve charges, the Department of Justice said Monday.
Why it matters: This is the largest criminal penalty in a U.S. antitrust case, and Sandoz is now the third company to admit guilt within the wide-ranging scheme to fix prices of generics, Axios' Bob Herman reports.
What we're watching: Sandoz, which said it was "disappointed" with this misconduct, admitted it rigged the prices of a handful of drugs — and implicated unnamed generic drugmakers in its deferred prosecution agreement:
The bottom line: This investigation is far from over and casts a pall over an industry that claims to get lower drug prices for patients.
Vice President Mike Pence speaks during a briefing yesterday on the administration's coronavirus response. Photo: Drew Angerer/Getty Images
Now that the coronavirus diagnostic test works, the next issue to grapple with is whether it's affordable.
Why it matters: People worried about getting hit with large medical bills if they get tested for the novel coronavirus may delay going to the doctor, or not go at all — the opposite of what needs to happen as public health officials seek to contain the virus' spread.
What they're saying: "We are very concerned about affordability and access. We want to incentivize private sector development while protecting patients from costs and making sure they get the interventions they need to control the spread," a senior White House official said.
Details: The CDC pays for the test, but that's unlikely to remain the case if and when it becomes available through private labs.
Case in point: New York Gov. Andrew Cuomo announced last night that insurers in the state will be required to waive cost-sharing associated with coronavirus testing, including emergency room, urgent care and office visits.
There are the Americans who are worried about paying for medical bills stemming from the coronavirus, and then there's the wealthy.
Between the lines: Viruses don't care about someone's income, but money can certainly buy extra precautions and assurances, as Bloomberg reports.
Details: The rich often have access to scientists and health experts that the rest of us don't have.
The bottom line: "Resources like money and transportation and information give people head starts on protective and preventive measures, and can help create more comfortable scenarios for people to cope with disasters," Jewel Mullen, associate dean for health equity at the University of Texas at Austin's Dell Medical School, told Bloomberg.